{"id":"voriconazole-low-dose","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Visual disturbances (blurred vision, photopsia)"},{"rate":"10-15","effect":"Hepatotoxicity (elevated liver enzymes)"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Photosensitivity"},{"rate":"5","effect":"Hallucinations"},{"rate":"5-10","effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Voriconazole is a triazole antifungal that selectively inhibits the cytochrome P450-dependent enzyme lanosterol 14α-demethylase (CYP51), which is essential for ergosterol biosynthesis in fungi. By blocking ergosterol production, the drug causes disruption of the fungal cell membrane integrity, leading to cell death. The low-dose formulation maintains antifungal efficacy while potentially reducing systemic exposure and associated adverse effects.","oneSentence":"Voriconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:48.906Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive aspergillosis"},{"name":"Candidemia and other Candida infections"},{"name":"Esophageal candidiasis"},{"name":"Scedosporium and Fusarium infections"}]},"trialDetails":[{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT06129734","phase":"PHASE1, PHASE2","title":"Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","status":"RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2025-07-28","conditions":"Myeloid Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05458102","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2022-08-19","conditions":"Human Immunodeficiency Virus Type 1 (HIV-1) Infection","enrollment":18},{"nctId":"NCT06680544","phase":"PHASE2","title":"Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2024-11-15","conditions":"Dermatophyte Infection","enrollment":120},{"nctId":"NCT05330000","phase":"PHASE1","title":"Comparative Study on Tolerance and Pharmacokinetics of Voriconazole for Injection in Healthy Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-05-22","conditions":"Healthy Adults","enrollment":48},{"nctId":"NCT04072640","phase":"EARLY_PHASE1","title":"Three Induction Treatments on Cryptococcal Meningitis","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-01-25","conditions":"Cryptococcal Meningitis, HIV/AIDS","enrollment":120},{"nctId":"NCT00836875","phase":"PHASE3","title":"A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children","status":"TERMINATED","sponsor":"Pfizer","startDate":"2009-05","conditions":"Invasive Aspergillosis","enrollment":31},{"nctId":"NCT01030653","phase":"PHASE4","title":"Pharmacokinetics of Voriconazole in Obese Subjects","status":"COMPLETED","sponsor":"Manjunath Prakash Pai","startDate":"2009-11","conditions":"Healthy","enrollment":10},{"nctId":"NCT00624143","phase":"PHASE3","title":"Antifungal Prophylaxis in Pediatric Acute Leukemia","status":"UNKNOWN","sponsor":"All India Institute of Medical Sciences","startDate":"2008-02","conditions":"Pediatric Acute Leukemia Induction","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":47,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vfend"],"phase":"marketed","status":"active","brandName":"Voriconazole low dose","genericName":"Voriconazole low dose","companyName":"Manjunath Prakash Pai","companyId":"manjunath-prakash-pai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voriconazole inhibits fungal lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}